Addressing highly unmet neurogenerative disorders such as Parkinson's and Alzheimer's diseases with multiple drug candidates through innovative delivery options.

our-science

Our Science

  • Excellent Animal Proof of Concept
  • Multiple mechanism of actions (MOAs)
  • Precision Medicine
  • Patient-focused Model

Pipeline

  • Our extraordinary multiple assets, unlike others
  • 8 drug candidates
  • Combo drugs
partners

Contact Us

Your opinion is important for us to understand and address these challenging neurodegenerative diseases. Please drop us a message if you are interested in learning more of our science and drug development program.

Press Releases

PennNeuroKnow

3 Notable Neuroscience Discoveries in 2021

Read More

EINPRESSWIRE

FHL Announces Phase 2 Clinical Trial for Parkinson’s Drug, Korean Medical Device Company Acquisition and Saudi JV

Read More

TechNow

Forest Hills Lab將向美國食品藥品監督管理局提交研究性新藥申請

Read More

PR Newswire

Forest Hills Lab將向美國食品藥品監督管理局提交研究性新藥申請

Read More

Parkinson’s News Today

Forest Hills Lab Asking to Open Phase 2 Trial of FHL-301 in Parkinson’s

Read More

Yahoo Finance

Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson’s disease with the US FDA

Read More